(Q77485583)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9794842%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

review article

1 reference

title

The role of CD4+ T cell responses in antitumor immunity (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9794842%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

author name string

D M Pardoll

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9794842%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

S L Topalian

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9794842%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

publication date

1 October 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9794842%20AND%20SRC:MED&resulttype=core&format=json

Current Opinion in Immunology

6 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9794842%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9794842%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9794842%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

page(s)

588-594

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9794842%20AND%20SRC:MED&resulttype=core&format=json

Principles for adoptive T cell therapy of human viral diseases

6 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

Regression of established murine carcinoma metastases following vaccination with tumour-associated antigen peptides

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

Tumor immunotherapy: the tumor cell as an antigen-presenting cell

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

Interleukin 7 induces CD4+ T cell-dependent tumor rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

Induction of antigen-specific T cell anergy: An early event in the course of tumor progression

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

B cells inhibit induction of T cell-dependent tumor immunity.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

Self antigens expressed by solid tumors Do not efficiently stimulate naive or activated T cells: implications for immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

Help for cytotoxic-T-cell responses is mediated by CD40 signalling

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

MHC class II restricted tumor antigens and the role of CD4+ T cells in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

Dominant TCRB-V-J chain usage and clonal expansion of sarcoma-reactive CD4+ HLA-DR-restricted T cells suggest a limited set of immunodominant sarcoma antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

T cells recognize the VH complementarity-determining region 3 of the idiotypic protein of B cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

Interactions between autologous CD4+ and CD8+ T lymphocytes and human squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

Characterisation of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

A case report: immune responses and clinical course of the first human use of granulocyte/macrophage-colony-stimulating-factor-transduced autologous melanoma cells for immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

A unique tumor antigen produced by a single amino acid substitution

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2898%2980228-8

7 January 2021

10.1016/S0952-7915(98)80228-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9794842%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference